Over the last couple of weeks, the biotech and pharma spaces have been inundated with product launches, partnership announcements, grant awards and breakthrough publications. Here, we highlight an AI platform optimizing biological discovery, a partnership supporting early-stage biotech companies in Korea and a US$2.2 million grant awarded by the Gates Foundation to develop implantable cell factory platforms that can deliver therapeutic antibodies over extended periods of two years or longer. Product Enabling a new genome-engineering strategy Full Circles Therapeutics (MA, USA) recently announced that its circular single-stranded DNA (cssDNA, C4DNA™) technology platform has been highlighted as a key enabling component of a new genome-engineering strategy. This was demonstrated in a recent study, conducted in collaboration with Benjamin Kleinstiver and Connor Tou at the Center for Genomic Medicine at Massachusetts General Hospital (MA, USA), which presents a method for inserting gene-scale DNA into the genome while avoiding the strong innate immune responses typically triggered by conventional double-stranded DNA donors. Read the full release >>> Optimizing biological discovery with Physical AI As AI reshapes the digital world through cognitive and generative capabilities, a new frontier emerges: physical AI – an intelligent system that perceives, reasons through and acts in the physical world. Recently, Bota Systems (Zürich, Switzerland) launched SAION AI, the first Physical AI platform for biomanufacturing. SAION AI is not limited to in silico design. Instead, it is a full-stack Physical AI platform integrating cognition, orchestration and closed-loop execution through end-to-end experimentation, and continuously optimizing biological discovery and biomanufacturing. Read the…
